Taltz ® (ixekizumab) injektion

För fullständig produktresumé för Taltz® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Taltz® ▼ (ixekizumab): Byte till annan biologisk behandling

Byte från ixekizumab till en annan biologisk har inte studerats av Eli Lilly and Company.


Clinical Trial Data

Switching from ixekizumab to a different biologic, including to a TNF inhibitor, has not been studied by Lilly in clinical trials.

Treatment Guidelines on Biologic Switching

Specific recommendations on switching from ixekizumab to another biologic are not available. 

  • The Joint American Academy of Dermatology and National Psoriasis Foundation 2019 guidelines on the treatment and management of psoriasis with biologics states no evidence-based studies have been conducted to determine the appropriate duration of time between discontinuation of the previous medication and initiation of a biologic. The guidelines suggest assessments should be done on a case-by-case basis considering many factors including
    • treatment being discontinued
    • disease severity
    • response to previous treatment, and
    • on expert opinion (some experts will begin administration of the new biologic as soon as it is available; whereas, others may wait 3 to 4 half-lives of the previous therapy before beginning the new biologic).1
  • The British Association of Dermatologists 2017 psoriasis guidelines for biologic therapies include to consider using a washout period of 1 month or the length of a treatment cycle (whichever is longer) when transitioning between biologic therapies.2
  • The Transitioning Therapies programme consensus published in 2014 recommends when switching from one biologic therapy to another to include the use of a washout period if the switch is made due to an AE and do not include a washout period if the switch is made due to a lack of efficacy. Initiation of the second biologic therapy occurs with the usual induction and maintenance dosages.3


1Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. http://dx.doi.org/10.1016/j.jaad.2018.11.057

2Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177:628-636. http://dx.doi.org/10.1111/bjd.15665

3Mrowietz U, de Jong EM, Kragballe K, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2014;28(4):438-453. http://dx.doi.org/10.1111/jdv.12118


AE = adverse event

Lilly = Eli Lilly and Company

PK = pharmacokinetics

TNF = tumor necrosis factor

Datum fӧr senaste ӧversyn 2019 M03 21

Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Klicka för att chatta är tillgänglig

Klicka för att chatta är offline

Skriv din fråga till oss